Imatinib Terminated Phase 2 Trials for Chronic Myeloproliferative Disorders Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00245128Imatinib Mesylate in Treating Patients With Myelofibrosis